GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » E10

Astellas Pharma (Astellas Pharma) E10 : $0.58 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Astellas Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.056. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.58 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Astellas Pharma's average E10 Growth Rate was -7.80% per year. During the past 3 years, the average E10 Growth Rate was 4.60% per year. During the past 5 years, the average E10 Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Astellas Pharma was 24.70% per year. The lowest was 4.60% per year. And the median was 13.70% per year.

As of today (2024-04-28), Astellas Pharma's current stock price is $9.55. Astellas Pharma's E10 for the quarter that ended in Dec. 2023 was $0.58. Astellas Pharma's Shiller PE Ratio of today is 16.47.

During the past 13 years, the highest Shiller PE Ratio of Astellas Pharma was 40.34. The lowest was 17.92. And the median was 23.66.


Astellas Pharma E10 Historical Data

The historical data trend for Astellas Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma E10 Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.69 0.72 0.68 0.66

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.66 0.61 0.59 0.58

Competitive Comparison of Astellas Pharma's E10

For the Drug Manufacturers - General subindustry, Astellas Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Shiller PE Ratio falls into.



Astellas Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.056/106.8000*106.8000
=0.056

Current CPI (Dec. 2023) = 106.8000.

Astellas Pharma Quarterly Data

per share eps CPI Adj_EPS
201403 0.033 95.700 0.037
201406 0.158 98.000 0.172
201409 0.144 98.500 0.156
201412 0.170 97.900 0.185
201503 0.080 97.900 0.087
201506 0.164 98.400 0.178
201509 0.224 98.500 0.243
201512 0.235 98.100 0.256
201603 0.122 97.900 0.133
201606 0.297 98.100 0.323
201609 0.224 98.000 0.244
201612 0.260 98.400 0.282
201703 0.171 98.100 0.186
201706 0.185 98.500 0.201
201709 0.175 98.800 0.189
201712 0.265 99.400 0.285
201803 0.106 99.200 0.114
201806 0.251 99.200 0.270
201809 0.227 99.900 0.243
201812 0.406 99.700 0.435
201903 0.148 99.700 0.159
201906 0.287 99.800 0.307
201909 0.345 100.100 0.368
201912 0.300 100.500 0.319
202003 0.030 100.300 0.032
202006 0.252 99.900 0.269
202009 0.114 99.900 0.122
202012 0.311 99.300 0.334
202103 -0.061 99.900 -0.065
202106 0.150 99.500 0.161
202109 0.200 100.100 0.213
202112 0.288 100.100 0.307
202203 -0.037 101.100 -0.039
202206 0.101 101.800 0.106
202209 0.274 103.100 0.284
202212 0.197 104.100 0.202
202303 -0.189 104.400 -0.193
202306 0.130 105.200 0.132
202309 -0.005 106.200 -0.005
202312 0.056 106.800 0.056

Add all the adjusted EPS together and divide 10 will get our e10.


Astellas Pharma  (OTCPK:ALPMY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Astellas Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=9.55/0.58
=16.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Astellas Pharma was 40.34. The lowest was 17.92. And the median was 23.66.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Astellas Pharma E10 Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (Astellas Pharma) Headlines